Directness matters
Research in opioid or mixed-substance populations may generate hypotheses, but it does not answer a methamphetamine-specific clinical question.
Methamphetamine and ibogaine · clinical brief
Evidence Review
A transparent synthesis of the limited human and preclinical literature on ibogaine in stimulant use disorders, with attention to study design, uncertainty, safety reporting, and regulatory context.
01 / Scope
What this review can and cannot establish
This page examines evidence relevant to methamphetamine and ibogaine rather than presenting ibogaine as a treatment. It separates direct evidence in stimulant-use populations from broader studies involving other substance-use disorders, because those populations, outcomes, and risks are not interchangeable.
For background on the subject covered across this site, the Methamphetamine And Ibogaine: A Clinical Brief frames the wider clinical context. Readers seeking the organization’s purpose and information standards can also consult the principles behind this independent resource.
Design matters
Case series and self-reported follow-up can describe experiences; they cannot reliably separate an intervention effect from other explanations.
02 / Human and preclinical record
A small, indirect, uneven evidence base
Ibogaine is a naturally occurring psychoactive alkaloid associated with plants in the ibogaine reference overview. Published human literature has historically included observational reports, retrospective accounts, and open-label settings, often involving polysubstance use or opioid dependence rather than methamphetamine use disorder alone.
These designs may record self-reported changes in craving, use, withdrawal, or well-being, but they commonly lack randomization, blinded outcome assessment, a comparison group, and consistent biological verification of substance use. Attrition and selective recruitment are especially important when participants are drawn from nonstandard or self-selected settings.
Preclinical mechanisms and uncontrolled human reports should be read as signals for further research, not as evidence that a benefit has been established for a particular stimulant-use population.
Animal and laboratory work can be useful for examining pharmacology and generating questions, yet translation to clinical outcomes remains uncertain. Regulatory context is equally material: the U.S. Drug Enforcement Administration’s scheduling information lists ibogaine among Schedule I controlled substances, which shapes research access and does not itself establish clinical effectiveness or safety.
03 / Study map
How to read the published record
The table below is deliberately conservative. It distinguishes direct methamphetamine evidence from broader or indirect work, and it avoids treating a reported outcome as a confirmed effect. Where the literature is observational or retrospective, limitations are part of the result.
| Year | Design | Population | Outcome measured | Major limitations |
|---|---|---|---|---|
| 1999 | Retrospective observational report | People with substance-use histories; not methamphetamine-specific | Participant-reported changes in substance use and withdrawal-related experience | No randomized comparator; self-selection; retrospective recall; mixed substances; limited ability to attribute outcomes. |
| 2017 | Open-label observational work | Primarily opioid-dependent participants; indirect for stimulant use disorders | Short-term withdrawal and symptom measures | Small samples; no blinding or control group; brief follow-up; findings not directly transferable to methamphetamine use disorder. |
| Ongoing / registered | Registered early-phase or observational studies | Varied substance-use populations | Safety, feasibility, symptoms, and exploratory substance-use outcomes | Registration does not establish results; populations and protocols differ; some records may be incomplete, updated, or unpublished. |
This is a high-level appraisal rather than a systematic review or medical recommendation. The absence of large, well-controlled methamphetamine-specific trials is a central limitation, not a minor caveat.
04 / Research gaps
Questions future work would need to answer
Registry records can identify research in progress, but they should not be treated as results. The ClinicalTrials.gov study registry is a useful place to distinguish registered protocols from completed, peer-reviewed evidence. A trial title, recruitment status, or planned outcome is not a demonstration of benefit.
Population definition
Studies would need clear diagnostic criteria, stimulant-use patterns, co-occurring substance use, and eligibility rules so readers can judge to whom findings might apply.
Outcome integrity
Research should prespecify outcomes, include meaningful follow-up, explain missing data, and distinguish self-report from independently verified measures.
Safety transparency
Protocols should report screening, adverse events, serious adverse events, discontinuations, and oversight in enough detail for informed appraisal.
Methodological priorities include adequately powered comparative trials where ethically and legally feasible, independent outcome assessment, transparent adverse-event reporting, and follow-up long enough to assess whether any observed change persists. The site’s safety considerations place those questions beside the broader uncertainty around potential harms.
05 / Interpretation guide
Reading low-quality or conflicting findings
Does this evidence establish efficacy for methamphetamine use disorder?
No. The available literature is limited, includes designs that cannot establish causation, and does not provide a robust basis for concluding efficacy in methamphetamine use disorder.
Why do uncontrolled studies require caution?
Without random assignment, a comparator group, and systematic follow-up, apparent changes can reflect selection, expectation, concurrent care, natural fluctuation, or loss to follow-up rather than the intervention itself.
What should readers look for in future research?
Useful studies would clearly define stimulant-use populations, prespecify outcomes, report adverse events and retention, use independent assessment, and make follow-up and missing-data methods transparent.
How should safety claims be weighed?
Look for complete reporting rather than reassuring language. The FDA’s drug-safety information illustrates why adverse-event evidence, labeling context, and careful risk communication matter when interpreting clinical claims.
Context before conclusions
Keep the evidence, uncertainty, and safety questions together.
This review is intended to help readers assess claims without converting limited evidence into medical advice or a treatment recommendation.